Company profile FULC
After 39 days of this quarter the interest is at 16.0. Based on that we can calculate that during remaining 52 days it will total up to 37.0. Fulcrum Therapeutics expected interest is significantly lower compared to same quarter last year (-78.7%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 63 | 96 52.4% QoQ | 206 114.6% QoQ | 127 -38.3% QoQ |
| 2020 | 102 61.9% YoY -19.7% QoQ | 110 14.6% YoY 7.8% QoQ | 156 -24.3% YoY 41.8% QoQ | 51 -59.8% YoY -67.3% QoQ |
| 2021 | 128 25.5% YoY 151.0% QoQ | 146 32.7% YoY 14.1% QoQ | 197 26.3% YoY 34.9% QoQ | 92 80.4% YoY -53.3% QoQ |
| 2022 | 127 -0.8% YoY 38.0% QoQ | 154 5.5% YoY 21.3% QoQ | 125 -36.5% YoY -18.8% QoQ | 61 -33.7% YoY -51.2% QoQ |
| 2023 | 174 37.0% YoY 185.2% QoQ | 111 -27.9% YoY -36.2% QoQ | 152 21.6% YoY 36.9% QoQ | 48 -21.3% YoY -68.4% QoQ |
| 2024 | 16 -90.8% YoY -66.7% QoQ | - | - | - |
The average 5 years interest of Fulcrum Therapeutics was 9.36 per week. The last year interest of Fulcrum Therapeutics compared to the last 5 years has changed by -11.65%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -17.96%.
There is not enough data for Losmapimod clinical trials to provide analysis
There is not enough data for Losmapimod clinical trials to provide correlation calculation
There is not enough data for Losmapimod clinical trials to provide analysis
There is not enough data for FTX-6058 clinical trial to provide analysis
There is not enough data for FTX-6058 clinical trial to provide correlation calculation
There is not enough data for FTX-6058 clinical trial to provide analysis
There is not enough data for Rare neuromuscular disorders to provide analysis
There is not enough data for Rare neuromuscular disorders to provide correlation calculation
There is not enough data for Rare neuromuscular disorders to provide analysis
There is not enough data for Genetic cardiomyopathies treatment to provide analysis
There is not enough data for Genetic cardiomyopathies treatment to provide correlation calculation
There is not enough data for Genetic cardiomyopathies treatment to provide analysis
There is not enough data for Pulmonary diseases drugs to provide analysis
There is not enough data for Pulmonary diseases drugs to provide correlation calculation
There is not enough data for Pulmonary diseases drugs to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Fulcrum Therapeutics news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 160 inf% QoQ | 132 -17.5% QoQ | 115 -12.9% QoQ |
| 2020 | 41 inf% YoY -64.3% QoQ | 56 -65.0% YoY 36.6% QoQ | 128 -3.0% YoY 128.6% QoQ | 43 -62.6% YoY -66.4% QoQ |
| 2021 | 88 114.6% YoY 104.7% QoQ | 108 92.9% YoY 22.7% QoQ | 86 -32.8% YoY -20.4% QoQ | 109 153.5% YoY 26.7% QoQ |
| 2022 | 212 140.9% YoY 94.5% QoQ | 121 12.0% YoY -42.9% QoQ | 141 64.0% YoY 16.5% QoQ | 115 5.5% YoY -18.4% QoQ |
| 2023 | 77 -63.7% YoY -33.0% QoQ | 116 -4.1% YoY 50.6% QoQ | 171 21.3% YoY 47.4% QoQ | 64 -44.3% YoY -62.6% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Fulcrum Therapeutics news was 7.98 per week. The last year interest of Fulcrum Therapeutics news compared to the last 5 years has changed by -9.9%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -16.59%.
There is not enough data for Fulcrum Therapeutics stock price to provide analysis
There is not enough data for Fulcrum Therapeutics stock price to provide correlation calculation
There is not enough data for Fulcrum Therapeutics stock price to provide analysis
There is not enough data for Fulcrum Therapeutics competitors to provide analysis
There is not enough data for Fulcrum Therapeutics competitors to provide correlation calculation
There is not enough data for Fulcrum Therapeutics competitors to provide analysis
After 39 days of this quarter the interest is at 33.0. Based on that we can calculate that during remaining 52 days it will total up to 77.0. Fulcrum Therapeutics -stock -company expected interest is significantly lower compared to same quarter last year (-72.9%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 52 | 255 390.4% QoQ | 214 -16.1% QoQ | 125 -41.6% QoQ |
| 2020 | 159 205.8% YoY 27.2% QoQ | 260 2.0% YoY 63.5% QoQ | 225 5.1% YoY -13.5% QoQ | 125 0.0% YoY -44.4% QoQ |
| 2021 | 163 2.5% YoY 30.4% QoQ | 134 -48.5% YoY -17.8% QoQ | 319 41.8% YoY 138.1% QoQ | 207 65.6% YoY -35.1% QoQ |
| 2022 | 233 42.9% YoY 12.6% QoQ | 278 107.5% YoY 19.3% QoQ | 136 -57.4% YoY -51.1% QoQ | 80 -61.4% YoY -41.2% QoQ |
| 2023 | 284 21.9% YoY 255.0% QoQ | 209 -24.8% YoY -26.4% QoQ | 238 75.0% YoY 13.9% QoQ | 122 52.5% YoY -48.7% QoQ |
| 2024 | 33 -88.4% YoY -73.0% QoQ | - | - | - |
The average 5 years interest of Fulcrum Therapeutics -stock -company was 14.75 per week. The last year interest of Fulcrum Therapeutics -stock -company compared to the last 5 years has changed by -3.53%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 8.38%.